A novel implantable therapy designed for men with neurogenic erectile dysfunction. CaverSTIM™ works directly on the nerves involved in erectile function, using targeted neuromodulation to help restore erectile function when medications are not enough. CaverSTIM™ is currently being evaluated in clinical studies, with a focus on men living with spinal cord injury.
CaverSTIM™ is designed to address nerve-related erectile challenges with precision and purpose
Directly supports cavernous nerve function rather than just managing symptoms.
For prostatectomy It intervenes during the critical post-surgical window when nerve recovery potential is highest.
For prostatectomy it's engineered to integrate smoothly into existing prostate cancer surgery workflows, adding no additional procedural complexity for surgeons or care teams.
No daily medications, pumps, or ongoing pharmaceutical interventions required.
Learn more about how our technology works
CaverSTIM™ introduces a new way of addressing erectile dysfunction after spinal cord injury or prostate cancer surgery by intervening early, at the point when nerve recovery is still possible. Instead of managing symptoms years later, the device is designed for placement during the primary surgical procedure, when targeted support can have the greatest impact.
By delivering focused neuromodulation during the critical post-operative healing period, CaverSTIM™ is engineered to help maintain and restore natural pelvic nerve function, with the goal of improving long-term erectile outcomes.
The system includes three coordinated components: an implantable electrode array placed during surgery, a subcutaneous pulse generator, and a clinician-controlled external programming interface.
.png)
Built on proven neuromodulation principles, CaverSTIM™ uses precisely calibrated electrical stimulation to support nerve activity in the cavernous nerves—the key pathways responsible for erectile function.
The system features:
CaverSTIM™ consists of three integrated components designed to work together to support nerve function recovery:
A step-by-step look at the CaverSTIM™ treatment pathway
CaverSTIM™ is implanted through minimally invasive laparoscopic surgery, which may be robot-assisted. The electrodes are positioned near the pelvic nerves involved in erectile function, while the stimulator is placed under the skin. The implant is fully contained within the body, with no components passing through the skin.
After few days of surgery, the clinical team activates the implanted stimulator and adjusts the stimulation settings for each patient. The system is programmed to provide targeted stimulation of the nerves involved in erectile function.
CaverSTIM™ is designed to provide both daily stimulation and on-demand use. Daily stimulation is intended to support nerve rehabilitation and help reinforce the pathways involved in erectile function, while on-demand stimulation can be activated by the patient when desired.
The clinical team monitors the patient's progress and, if needed, can adjust the stimulation settings to further personalize the therapy. The system can be programmed wirelessly, allowing adjustments to be made without additional procedures.
CaverSTIM™ is being evaluated through a multi-stage clinical development program designed to assess safety, feasibility, and potential benefit in restoring erectile nerve function after prostate cancer surgery. Our global studies follow rigorous scientific and regulatory standards to build a strong foundation for future approval.
CaverSTIM™ is an investigational device and is not approved for commercial use. Safety and efficacy have not yet been established.
Whether you're a healthcare provider, researcher, or patient seeking information about CaverSTIM™, we're here to help. Connect with our team to discuss clinical trials, research opportunities, or general inquiries.
Comphya is a Swiss clinical-stage medical device company developing CaverSTIM™, an implantable neuromodulation system intended to support nerve function following spinal cord injury or radical prostatectomy.